I find myself spending a lot of time looking at pharma through the same lens we use for every other company on Naftiko Signals — the services they deploy, the tools they hire for, the standards they reference, the press they let out into the world. Pharma is one of the hardest verticals to read this way. It is heavily regulated, IP-heavy by design, and culturally trained to say as little as possible about how the sausage gets made. So when I open up the Novo Nordisk Signals page and see a total signal score of 0 across services, tools, standards, languages, and concepts — with zero job postings and zero press releases parsed — that is not a bug in the data. That is the report.
The empty page is the signal
Novo Nordisk is the Danish pharmaceutical giant behind Ozempic and Wegovy, the world leader in diabetes care, and one of the most-talked-about companies on the planet right now because of GLP-1. If you read the analyst coverage you would think the company is in the middle of an AI-and-data renaissance — drug discovery models, manufacturing digital twins, real-world-evidence platforms, agentic regulatory submissions. None of that shows up in the public surface area Naftiko ingests. The services layer is empty. The integrations layer is empty. The governance layer is empty. The board-room narrative and the public engineering footprint are not in the same room.
Why pharma reads quiet
That gap is the most honest thing I can say about pharma from the outside. Naftiko’s methodology looks at what a company is hiring for, what it is announcing, and what specifications, tools, and services it is referencing in the open. A consumer SaaS company throws that exhaust off in every direction — AWS this, Snowflake that, OpenAI integration here, Kubernetes there. A regulated pharma giant runs the same workloads behind a much smaller door. Job postings get scrubbed of vendor names. Press releases stay clinical. Standards work happens inside HL7 and IDMP working groups that do not show up on a careers page. The signal is quieter, but the quiet itself is a signal.
Three gaps the quiet implies
What does that quiet imply for Novo Nordisk specifically? Three things, and they line up with the recommendations the Impact Report surfaces. First, no detected API surface area means there is no public connective tissue — no enterprise gateway, no service catalog, no OpenAPI footprint that an AI agent could navigate. Second, no detected AI governance signals against a backdrop of an AI-heavy executive narrative is the gap I would expect to see if a council exists internally but has not been formalized in public hiring. Third, no detected data-pipeline or event-driven signals against a manufacturing and clinical-trial operation that has to be running on Kafka-class infrastructure tells me the platform exists, but it is not being talked about as a platform. Each of those gaps is the difference between running the workload and being able to scale, govern, and partner around the workload.
This is where I think pharma is going to feel the capability-first shift hardest. The next decade of AI in life sciences is not going to be won by whoever has the biggest model. It is going to be won by whoever can expose drug-discovery, clinical-trial, regulatory-submission, manufacturing, and supply-chain workflows as reusable capabilities that agents and partners can consume. Right now, from the outside, Novo Nordisk does not look like a company doing that work in public — and the companies that win the GLP-1-and-everything-after era are the ones that will.
What would change the score
What’s Next. Two capability recommendations from where I sit. One: stand up a publicly discoverable API surface for non-IP-bearing functions — distributor onboarding, patient-support integrations, real-world-evidence partner access — so the integration layer stops being invisible. Two: charter a formal AI governance council and let the hiring show, because in a regulated category the governance posture is the AI strategy. Both move a 0 into the single digits, and both make Novo Nordisk legible to the next generation of agents, partners, and analysts looking at the company through Signals.
Full Signals page: https://companies.naftiko.io/signals/novo-nordisk/cxR5UrlFyP/.
